A Closer Look Into the Role of Compounding Pharmacies

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug across 120 low- and lower-middle-income countries over the next three years.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

The Craigavon investment enhances Almac’s global clinical supply network with upgraded storage, distribution, and shipping capabilities to meet the growing demand for temperature-sensitive medicines.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.